Last updated: May 1, 2026, 5:06 am
PSMO-09 - 83 - Neurodegenerative diseases: From innovation to patient impact
Tracks
Track 5
| Monday, August 31, 2026 |
| 2:30 PM - 4:00 PM |
Details
Organised by the FIP New Generation of Scientists Special Interest Group in collaboration with the FIP Early Career Pharmaceutical Group, the FIP Hospital Pharmacy Section and the FIP Industrial Pharmacy Section
Chair(s)
Ms Nikolina Biskic, Executive Committee Associate Member, the FIP Industrial Pharmacy Section, Croatia & Prof. Michael Ward, Co-chair, FIP Congress Programme Development Group, Australia
Introduction:
This session explores how innovation in neurodegenerative disease research translates into clinical practice and improves patients’ quality of life. It aims to connect scientists developing novel therapeutic approaches -such as metabolic, gene, or cell-based interventions with pharmacists providing care and supporting patients and families in daily disease management. The session will also emphasise the importance of interdisciplinary collaboration and communication between researchers, practitioners, and caregivers.
In line with the congress theme, the session will highlight how scientific innovation translates into integrated care pathways and tangible patient outcomes, with pharmacists playing a key role across research, clinical implementation, and long-term patient support.
Programme:
Learning objectives:
1. Illustrate how innovation in neurodegenerative research translates to patient-centred pharmacy practice.
2. Identify pharmacists’ roles in supporting patients and families through complex care.
3. Highlight intergenerational and interdisciplinary collaboration as a driver of translational success.
Take home messages:
Connecting discovery and practice empowers pharmacists and scientists to deliver better care for patients and families living with neurodegenerative diseases.
FIP Development Goals:
To learn more about these FIP Development Goals, click on the links below.
FIP Development Goal 2: Early Career Training Strategy
FIP Development Goal 7: Advancing Integrated Services
FIP Development Goal 15: People-Centred Care
| 14:30 – 14:40 | Introduction by the chairs |
| 14:40 – 15:00 | Advanced treatments for neuromuscular disorders: Real world experiences in a global population |
| Ms Christina Hellauer, Children’s Hospital of The King’s Daughters, USA | |
| 15:00 – 15:20 | Pharmacist practitioner: Innovating neurodegenerative disease pathways: Early cognitive decline screening through community pharmacy services |
| Mr Gonzalo Miguel Adsuar Meseguer, Cardenal Herrera University, Spain | |
| 15:20 – 15:55 | Panel discussion with chairs, speakers and additional panellists |
| 15 :55 – 16:00 | Closing remarks by the chairs |
Chairs & speakers
Mr Gonzalo M. Adsuar Meseguer
Cardenal Herrera University
Pharmacist practitioner: Innovating neurodegenerative disease pathways: Early cognitive decline screening through community pharmacy services
Ms Nikolina Biskic
Executive Committee associate member of the FIP Industrial Pharmacy Section
Chairing of 83 - Neurodegenerative diseases: From innovation to patient impact
Ms Christina Hellauer
Children’s Hospital of The King’s Daughters
Advanced treatments for neuromuscular disorders: Real world experiences in a global population
Prof. Michael Ward
Co-chair FIP Congress Programme Development Group
Chairing of 83 - Neurodegenerative diseases: From innovation to patient impact